中国P站

Monitoring for renal transplant rejection is a critical aspect of ensuring long-term graft survival, and significant advancements have been made in developing non-invasive surveillance strategies. These emerging methods aim to provide early detection of rejection episodes with greater sensitivity and specificity, thereby potentially reducing the reliance on traditional invasive procedures. One such promising biomarker is donor-derived cell-free DNA (dd-cfDNA), which has demonstrated its utility in identifying rejection early on [1].

The evolving landscape of antibody-mediated rejection (AMR) in kidney transplantation necessitates a comprehensive understanding of its diagnostic criteria and therapeutic approaches. Contemporary reviews delve into the intricate details of AMR, emphasizing the integration of serological and histological findings for accurate diagnosis. The efficacy of various therapeutic interventions, including established and novel agents, is also a focal point in managing this complex form of rejection [2].

Gene expression profiling (GEP) has emerged as a powerful tool for differentiating various causes of renal allograft dysfunction. This technique offers a more precise diagnostic capability compared to traditional methods, enabling the distinction between T-cell mediated rejection (TCMR), AMR, and other forms of graft injury. Such precision is invaluable for tailoring immunosuppressive regimens effectively [3].

The role of donor-derived cell-free DNA (dd-cfDNA) as a real-time indicator of kidney transplant rejection is being increasingly recognized. Research indicates that elevated dd-cfDNA levels can precede detectable changes in serum creatinine, allowing for earlier intervention and potentially preventing irreversible graft damage. The correlation of dd-cfDNA levels with rejection severity further underscores its clinical significance [4].

Monitoring for chronic active antibody-mediated rejection (CAAMR) presents unique challenges in kidney transplant recipients. While current diagnostic tools have limitations, emerging strategies focus on identifying and managing this insidious form of rejection. The assessment of donor-specific antibodies over time and the development of predictive models are key areas of investigation [5].

Artificial intelligence (AI) is revolutionizing the interpretation of kidney transplant biopsy slides for rejection monitoring. AI algorithms show remarkable potential in enhancing diagnostic accuracy and efficiency by detecting subtle rejection indicators that might be overlooked by human observers. This advancement promises more standardized and reproducible pathological assessments [6].

The predictive value of donor-specific antibody (DSA) monitoring in kidney transplant recipients is a significant area of research. Serial measurements of DSA levels and their characteristics, such as mean fluorescence intensity (MFI) and complement deposition, are crucial for identifying high-risk patients, particularly those susceptible to AMR, and for guiding immunosuppressive therapy adjustments [7].

Urinary biomarkers represent a promising avenue for the non-invasive assessment of renal transplant rejection. Various urinary molecules are being investigated for their potential to detect or predict rejection episodes, offering a less invasive alternative to traditional methods. This approach holds the potential to transform routine graft surveillance [8].

MicroRNAs (miRNAs) are gaining attention as diagnostic and prognostic markers in renal transplantation. Their altered expression patterns in the context of rejection make them valuable non-invasive indicators of graft injury. Furthermore, miRNAs are being explored as potential therapeutic targets, opening new avenues for treatment [9].

The comparison between protocol biopsies and non-invasive monitoring for detecting subclinical rejection in kidney transplant recipients highlights the evolving diagnostic paradigm. While protocol biopsies remain the gold standard, the increasing utility of non-invasive markers like dd-cfDNA and GEP is crucial for early detection and management, potentially reducing the need for frequent biopsies [10].

Description

The critical importance of monitoring renal transplant rejection for long-term graft survival is underscored by recent advancements in non-invasive surveillance strategies. These methods, including the use of donor-derived cell-free DNA (dd-cfDNA) as a sensitive biomarker, aim to achieve early detection of rejection episodes, thereby reducing the necessity for routine protocol biopsies. Furthermore, gene expression profiling and proteomic analysis are being utilized to identify specific rejection pathways and personalize immunosuppressive therapy [1].

Antibody-mediated rejection (AMR) in renal transplantation is a complex area that has seen significant review and exploration. Contemporary reviews focus on the evolving diagnostic criteria for AMR, emphasizing the combined importance of serological and histological findings. The efficacy of various therapeutic strategies, encompassing plasma exchange, intravenous immunoglobulin, and targeted therapies like rituximab and eculizumab, for managing AMR is also thoroughly examined [2].

The utility of gene expression profiling (GEP) in distinguishing different types of renal allograft dysfunction is a key area of investigation. Studies demonstrate GEP's capability to differentiate between active T-cell mediated rejection (TCMR), AMR, and other causes of graft injury, offering a more precise diagnosis than conventional methods. This enhanced diagnostic precision facilitates the implementation of more targeted and effective immunosuppressive regimens [3].

The role of donor-derived cell-free DNA (dd-cfDNA) as a real-time indicator of kidney transplant rejection is being extensively studied. Findings suggest that increases in dd-cfDNA levels can predict acute rejection episodes earlier than alterations in serum creatinine, enabling timely interventions and potentially averting irreversible graft damage. The correlation of dd-cfDNA levels with the severity of rejection further solidifies its diagnostic value [4].

Challenges and advancements in monitoring kidney transplant recipients for chronic active antibody-mediated rejection (CAAMR) are being addressed. The limitations of current diagnostic tools are acknowledged, and emerging strategies for identifying and managing this insidious form of rejection are highlighted. These include the longitudinal assessment of donor-specific antibodies and the development of predictive models for risk stratification [5].

Artificial intelligence (AI) is making significant inroads into the pathological interpretation of kidney transplant biopsy slides for rejection monitoring. AI algorithms demonstrate promise in improving both the accuracy and efficiency of pathological diagnoses by identifying subtle rejection indicators that may elude human observation. This technological integration is expected to lead to more standardized and reproducible assessment processes [6].

The predictive value of donor-specific antibody (DSA) monitoring in kidney transplant recipients is a well-established concept that continues to be refined. Serial measurements of DSA levels, along with their specific characteristics such as mean fluorescence intensity (MFI) and complement deposition, are instrumental in identifying patients at elevated risk of rejection, particularly AMR. This information guides necessary adjustments to immunosuppressive therapy [7].

Urinary biomarkers offer a compelling approach to the non-invasive assessment of renal transplant rejection. The article reviews various urinary molecules, including NGAL, MCP-1, and KIM-1, and their potential to detect or predict rejection episodes. This non-invasive strategy presents a promising alternative to more invasive diagnostic procedures [8].

MicroRNAs (miRNAs) are being recognized for their potential as diagnostic and prognostic markers in renal transplantation. The study of altered miRNA expression in the context of rejection reveals their capacity to serve as non-invasive indicators of graft injury. Furthermore, miRNAs are being investigated as potential therapeutic targets, offering novel treatment avenues [9].

This study evaluates the effectiveness of protocol biopsies against clinical monitoring and non-invasive markers for the detection of subclinical rejection in kidney transplant recipients. While protocol biopsies remain the definitive diagnostic standard, advancements in non-invasive surveillance, particularly dd-cfDNA and GEP, are proving increasingly valuable in identifying early rejection and informing management decisions, potentially reducing the frequency of invasive biopsies [10].

Conclusion

This collection of research explores advancements in monitoring renal transplant rejection. It highlights non-invasive strategies such as donor-derived cell-free DNA (dd-cfDNA) and gene expression profiling (GEP) for early detection and personalized therapy. The review covers antibody-mediated rejection (AMR), its diagnosis and treatment, and the challenges of chronic active AMR. Artificial intelligence in pathology and the predictive value of donor-specific antibodies (DSA) are also discussed. Urinary biomarkers and microRNAs (miRNAs) are presented as promising non-invasive indicators. The comparison between protocol biopsies and non-invasive monitoring suggests a shift towards earlier detection and potentially reduced invasive procedures.

References

1. Abdel-Khalek, M, Simoons, S, Mehta, S. (2022) .Am J Transplant 22:1827-1839.

   , ,

2. Momeni, A, Rana, MU, Sands, M. (2023) .Transplant Rev (Orlando) 37:100960.

   , ,

3. Soares, M, Simoons, S, Shishido, S. (2021) .Am J Transplant 21:1982-1992.

   , ,

4. Levy, MS, Simoons, S, Akkad, E. (2022) .JAMA 327:1568-1578.

   , ,

5. Simoons, S, El-Ghoneimi, T, Ezon, B. (2021) .Curr Opin Organ Transplant 26:172-179.

   , ,

6. Yao, Q, Simoons, S, Liu, Z. (2023) .Kidney Int 104:1487-1497.

   , ,

7. Simoons, S, Soares, M, Wiebe, N. (2021) .Clin J Am Soc Nephrol 16:1629-1639.

   , ,

8. Simoons, S, Abdel-Khalek, M, Vella, JP. (2022) .Front Immunol 13:853042.

   , ,

9. Simoons, S, Momeni, A, Rana, MU. (2023) .Cells 12:2890.

   , ,

10. Simoons, S, Soares, M, El-Ghoneimi, T. (2022) .J Clin Med 11:5416.

    , ,